Biotech Stocks Lose Momentum With Greece Crisis; Blockbuster Immunotherapy Deal

The biotech sector is usually immune to macro events but today the crisis in Greece gave investors an excuse to take profits. Many biotech stocks and ETFs were down over 3% faring worse than the NASDAQ down 2.4%.